New hope for myelofibrosis patients who Can't take standard therapy
NCT ID NCT05835466
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 38 times
Summary
This study tests an oral drug called reparixin in 26 adults with high-risk myelofibrosis who cannot take or refuse standard JAK inhibitor therapy. The goal is to see if reparixin can shrink the spleen, improve anemia, and reduce symptoms over 6 months. Participants who respond well may continue treatment long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (PMF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
-
NewYork-Presbyterian/Weill Cornell Medical Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact
-
Ruttenberg Treatment Center
RECRUITINGNew York, New York, 10029, United States
Contact
-
The Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
Contact
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
Contact
-
Wake Forest Baptist Health Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.